| 10.15 0.02 (0.2%) | 08-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.93 | 1-year : | 13.94 |
| Resists | First : | 10.22 | Second : | 11.93 |
| Pivot price | 10.13 |
|||
| Supports | First : | 10.13 | Second : | 10.07 |
| MAs | MA(5) : | 10.13  |
MA(20) : | 10.13 |
| MA(100) : | 9.08 |
MA(250) : | 8.83 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.6 |
D(3) : | 34.8 |
| RSI | RSI(14): 54.7 | |||
| 52-week | High : | 17.62 | Low : | 4.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ITOS ] has closed below upper band by 41.6%. Bollinger Bands are 90.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.17 - 10.22 | 10.22 - 10.26 |
| Low: | 10.01 - 10.08 | 10.08 - 10.13 |
| Close: | 10.05 - 10.16 | 10.16 - 10.24 |
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Thu, 23 Oct 2025
iTeos Therapeutics, Inc. (ITOS) Stock Analysis: Exploring the Biotech’s Financial and Growth Potential - DirectorsTalk Interviews
Fri, 29 Aug 2025
iTeos Therapeutics completes merger with Concentra Biosciences, delists from Nasdaq - Investing.com
Mon, 21 Jul 2025
iTeos Therapeutics To Be Acquired by Concentra Biosciences - citybiz
Mon, 21 Jul 2025
iTeos Therapeutics, Inc. Enters Merger Agreement with Concentra Biosciences, LLC for $10.047 per Share Acquisition - Nasdaq
Mon, 21 Jul 2025
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders - Business Wire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 0.3 (%) |
| Held by Institutions | 90.2 (%) |
| Shares Short | 2,060 (K) |
| Shares Short P.Month | 3,070 (K) |
| EPS | -4.74 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.89 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -18.5 % |
| Return on Equity (ttm) | -35 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -4.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -108 (M) |
| Levered Free Cash Flow | -22 (M) |
| PE Ratio | -2.15 |
| PEG Ratio | 0 |
| Price to Book value | 0.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|